⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorolithium SCHEMBL28928073 | 0.96 | — | — | |
| SCHEMBL4892 | 0.91 | — | — | |
| Lithium SCHEMBL29921052 | 0.86 | — | — | |
| Water SCHEMBL2111673 | 0.86 | ALDH1A1 (0.33) | — | |
| Ammonia Solution, Strong SCHEMBL3719693 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL23834950 | 0.86 | — | — | |
| SCHEMBL662853 | 0.86 | — | — | |
| SCHEMBL21680827 | 0.86 | — | — | |
| Magnesium Chloride Anhydrous SCHEMBL28452074 | 0.86 | — | — | |
| Methyl Alcohol SCHEMBL28084859 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4225321-A1 | PROCESS FOR BORON-CONTAINING COMPOUNDS | Venatorx Pharmaceuticals, Inc. (US) | 2023-08-16 | — | — | EP | claimed |
| WO-2020040433-A1 | METHOD FOR PREPARATION OF SGLT-2 INHIBITOR, DAPAGLIFLOZIN PRECURSOR | 동아에스티 주식회사 | 2020-02-27 | — | — | WO | claimed |
| CN-104736532-A | Improved process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine | NOVARTIS AG | 2015-06-24 | — | — | CN | claimed |
| EP-3921307-B1 | PYRAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-06-26 | — | — | EP | disclosed |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-04 | — | — | US | disclosed |
| US-20240083857-A1 | 2-Methyl-Quinazolines | Bayer Pharma AG (DE) | 2024-03-14 | — | — | US | disclosed |
| US-11884672-B2 | Modulators of alpha-1 antitrypsin | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-01-30 | — | — | US | disclosed |
| EP-3601284-B1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | HOFFMANN LA ROCHE (CH) | 2023-12-27 | — | — | EP | disclosed |
| US-11851420-B2 | Pyrazole derivatives | SYNGENTA CROP PROTECTION AG (CH) | 2023-12-26 | — | — | US | disclosed |
| WO-2023180189-A1 | MPRO TARGETING ANTIVIRAL COMPOUNDS | EXSCIENTIA AI LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| US-20230301300-A1 | HERBICIDAL COMPOSITIONS | SYNGENTA CROP PROTECTION AG (CH) | 2023-09-28 | — | — | US | disclosed |
| CN-106008317-A | Polycyclic tetracycline compounds | 四相制药公司 | 2016-10-12 | — | — | CN | disclosed |
| US-20160175306-A1 | COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | US | disclosed |
| CN-103370306-B | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-12-02 | — | — | CN | disclosed |
| CN-104744370-A | Glucagon receptor modulators | PFIZER | 2015-07-01 | — | — | CN | disclosed |
| CN-104736532-A | Improved process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine | NOVARTIS AG | 2015-06-24 | — | — | CN | disclosed |
| US-20150104526-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-16 | — | — | US | disclosed |
| CN-103003266-A | Hydroxyalkylbenzylpyrazoles and their use for the treatment of hyperproliferative and angiogenic diseases | BAYER IP GMBH | 2013-03-27 | — | — | CN | disclosed |
| CN-102516161-A | Pyridine and pyrimidine derivatives as mglur2 antagonists | HOFFMANN LA ROCHE | 2012-06-27 | — | — | CN | disclosed |
| CN-101415681-A | Pyridine and pyrimidine derivatives as mGluR2 antagonists | HOFFMANN LA ROCHE (CH) | 2009-04-22 | — | — | CN | disclosed |